enGene Holdings Inc.
Clinical-stage biotech developing non-viral gene therapies for local delivery.
ENGN | US
Overview
Corporate Details
- ISIN(s):
- CA29286M1059
- LEI:
- Country:
- United States of America
- Address:
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT
- Website:
- https://engene.com/
- Sector:
- Manufacturing
Description
enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral gene therapies. The company's proprietary platform is designed for the local delivery of DNA-based immunotherapies directly to mucosal tissues and other organs. Its lead product candidate, EG-70 (detalimogene voraplasmid), is an intravesical therapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapeutic approach aims to stimulate a patient's own immune system to attack tumor cells. By avoiding viral vectors, enGene seeks to create re-dosable genetic medicines that can be administered without the complexities and potential immunogenicity associated with viral-based systems, with the goal of making gene-based treatments more accessible.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all enGene Holdings Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for enGene Holdings Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for enGene Holdings Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
